作 者丨见习记者 李益文 编 辑丨曾静娇 5月28日晚间，嘉应制药（002198.SZ）发布公告称，公司于当日收到中国证监会的《立案告知书》，因其涉嫌信息披露违法违规，证监会决定对公司立 案。 3月12日，公司副总经理、董事会秘书肖巧霞以"推进公司治理现代化，提升企业透明度与市场信任度"等缘由向公司董事会辞去上述职务，同 时，辞去非独立董事职务。同日，公司非独立董事黎林亦同步请辞。 对此，南财快讯记者以投资者身份致电嘉应制药，接线人员表示， 公司已关注到高管流动性较大的问题。近期公司二股东加入后，公司经营方 面有了新变化，这一过程中有人员流动属正常情况。 公告并未披露违法违规的具体细节，嘉应制药表示，公司将积极配合中国证监会的相关工作，并严格按照规定及监管要求履行信息披露义务。 值得注意的是，在公司遭证监会立案前三个月内，嘉应制药已出现高管"离职潮"。 根据嘉应制药此前公告披露，5月20日，公司财务总监史俊平因个人原因申请辞职，辞任后不再担任公司任何职务。4月11日，证券事务代表陈 裕强因个人原因申请辞职，辞职后将不再担任公司任何职务。 上述工作人员还透露， 目前公司财务总监一职已有合适人员，后续会按照规定流 ...

此外，独立董事李善伟的违规行为也令人咋舌。2024年12月，李善伟因隐瞒持股信息并在内幕信息敏感 期违规减持股票，被广东证监局采取责令购回违规减持股份的行政监管措施。其行为严重违反了信息披 露相关规定，损害了市场的公平性和投资者的利益。 嘉应制药此前还出现了多名高管职务异动，无疑给公司带来了更大的不确定性。 关联交易不规范是嘉应制药的一大问题。2024年第四季度，公司与养天和大药房股份有限公司及其关联 公司发生多笔关联交易，涉及金额高达1039.94万元，却未及时履行审议程序和披露，直至2025年4月才 补充披露。这种不规范操作严重损害了信息披露的及时性和准确性，让投资者难以及时了解公司的真实 经营状况。 资金管理漏洞同样严重。2024年9月至2025年1月期间，嘉应制药被关联方湖南药聚能医药有限公司非经 营性占用资金2.35亿元，且通过"月初转出、月末前转回"的方式粉饰痕迹，直至2025年1月23日才全部 归还。这种行为不仅违反了资金管理规定，也暴露了公司内部治理的混乱。 每经评论员 杜宇 5月28日晚间，嘉应制药（SZ002198，前收盘价：6.70元，市值：34亿元）公告因涉嫌信息披露违法违 规被证监会 ...

嘉应制药（002198）一字跌停，公司公告涉嫌信息披露违法违规，遭中国证监会立案。 暗盘资金正涌入这些股票，点击速看>>> ...

Group 1 - The overall market liquidity remains tight, with structural market conditions leading to rotations in new consumption and new manufacturing sectors [1][18] - There are left-side investment opportunities in fields such as robotics, intelligent driving, and internet platforms [1][18] - The basic chemical industry is currently undervalued, presenting medium to long-term investment potential [18] Group 2 - The performance of sectors like consumption and pharmaceuticals is expected to be relatively stable, with short-term elasticity likely to be better [18] - The chemical industry is anticipated to see structural opportunities and valuation recovery in 2025, driven by policy stimulus and improving demand [18] - The supply side of the chemical industry is experiencing a slowdown in capital expenditure and new capacity growth, which will take time to digest [18]

Policy Developments - The National Medical Products Administration (NMPA) held a meeting on May 28 to discuss the "Clearing Source" action in the drug distribution sector, emphasizing strict enforcement of regulations and collaboration across departments to ensure drug quality and safety [2]. Drug and Device Approvals - Novartis announced on May 28 that its anti-VEGF monoclonal antibody, Brolucizumab, has been approved by the NMPA for the treatment of diabetic macular edema (DME), allowing for injections every three months after the loading phase [4]. - On the same day, the NMPA accepted the new drug application (NDA) for Rocbrutinib, a fourth-generation BTK inhibitor developed by LuPeng Pharmaceutical, which is intended for adult patients with mantle cell lymphoma (MCL) who have previously received BTK inhibitor treatment [5]. Capital Market Activities - Zhenmai Bio completed a C+ round financing of 280 million yuan on May 28, with participation from multiple investors, aiming to focus on "commercial ecosystem construction" and "global expansion" [7]. Industry Events - On May 27, Anmai Bio announced a global licensing agreement with Juri Biosciences for the development of KLK2 and CD3 T-cell engaging molecules for metastatic prostate cancer, with potential payments up to 210 million USD [9]. - Eli Lilly announced on May 27 that it will acquire SiteOne Therapeutics, a startup focused on developing sodium channel inhibitors for pain management, with a total deal value of up to 1 billion USD [10]. Regulatory and Compliance Issues - ST Longjin announced on May 28 that it received a decision from the Shenzhen Stock Exchange to terminate its stock listing, effective June 27, 2025, due to non-compliance with listing rules [12]. - ST Jiyuan's stock will be delisted on May 29, 2025, after failing to maintain a closing price above 1 yuan for 20 consecutive trading days [14]. - ST Suwu reported on May 28 that it is under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, but its daily operations remain normal [15]. - Jiaying Pharmaceutical announced on May 28 that it is under investigation by the CSRC for suspected information disclosure violations and will cooperate with the regulatory body [16].

Core Viewpoint - The company, Jiaying Pharmaceutical, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact its operations and reputation [1]. Group 1: Company Overview - Jiaying Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine, holding a significant position in the industry with 58 drug varieties across 5 dosage forms [3]. - The company's leading products, Shuangliao Houfeng San and Zhonggan Ling Pian, have been recognized as national protected traditional Chinese medicine varieties and have won the "Guangdong Province Famous Brand Product" title [3]. - Jiaying Pharmaceutical's subsidiary, Jiaying Hunan, produces unique products listed in the national medical insurance directory, including Jieguzhi Qili Pian and Jieguzhi Qili Jiao Nang, both of which have patent authorization [3]. Group 2: Financial Performance - In 2024, Jiaying Pharmaceutical reported total revenue of 376 million yuan, a year-on-year decline of 29.46%, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% [3]. - Despite the financial challenges, the company has implemented measures such as optimizing production processes and enhancing cost control to maintain stable core business operations [3]. - In Q1 2025, Jiaying Pharmaceutical achieved revenue of 122 million yuan, a year-on-year increase of 28.83%, primarily due to expanded sales channels [3]. - The net profit attributable to shareholders for the same period was 15.40 million yuan, reflecting a significant year-on-year growth of 197.23%, driven by successful partnerships with major retail chains and improved cost management [3]. Group 3: Corporate Governance - During a recent earnings briefing, the company addressed investor concerns regarding its governance, stating that the current Secretary of the Board was recruited from a state-owned enterprise, emphasizing high compliance management standards [4]. - The company has undertaken substantial efforts in compliance and internal control, including appointing dedicated compliance personnel and implementing electronic process management [4]. - Future plans include enhancing compliance systems and culture, ensuring business operations and information disclosures are compliant and scientifically managed [4].

Group 1 - Jia Ying Pharmaceutical is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [2] - ST United plans to acquire 100% of Run Tian Industrial through a combination of share issuance and cash payment, with the stock set to resume trading on May 29 [3] - Long Gao Co., Ltd. is undergoing a restructuring of its controlling shareholder, Longyan Investment Development Group, which has established a new investment development group with a registered capital of 3 billion yuan [4] Group 2 - San You Chemical's controlling shareholder intends to inject 100 million yuan into its subsidiary, Tangshan San You Silicon Industry, through a private agreement [5] - ST Ji Pharmaceutical's stock will be delisted on May 29, 2025, due to a continuous closing price below 1 yuan for twenty trading days [6] - Hehe Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [8] Group 3 - ST Huaxi has signed a significant contract worth approximately 2.9 billion USD (about 20.84 billion yuan) for a project in Iraq, which represents 80.38% of its latest audited revenue [9] - ST Longjin's stock will enter a delisting preparation period starting June 6, 2025, following a decision by the Shenzhen Stock Exchange [10] - Zhenbao Island's wholly-owned subsidiary intends to acquire a 49% stake in its controlling subsidiary, Guizhou Shennong Valley [11]

Macro Dynamics - The Chinese Foreign Ministry urged the U.S. to ensure the legitimate rights and interests of international students, including Chinese students, amid reports of a halt in student visa issuance [1] - China announced a trial visa exemption policy for Saudi Arabia, Oman, Kuwait, and Bahrain from June 9, 2025, to June 8, 2026, allowing ordinary passport holders from these countries to enter China without a visa for up to 30 days [2] Market Data - From May 1 to 25, the retail sales of passenger cars in China reached 1.358 million units, a year-on-year increase of 16%, with a cumulative retail of 8.23 million units for the year, up 9% [3] - The retail sales of new energy vehicles during the same period were 726,000 units, marking a 31% year-on-year increase, with a penetration rate of 53.5% [3] - From January to April, the total profit of state-owned enterprises was 1.34914 trillion yuan, a year-on-year decrease of 1.7% [4] Company Dynamics - China’s Ministry of Education reported that the number of candidates for the national college entrance examination in 2025 is expected to reach 13.35 million [5] - The first-instance trial of former chairman of Everbright Trust, Yan Guijun, for bribery and abuse of power began, with allegations of illegal loan approvals totaling over 6.39 billion yuan [7] - Stellantis announced Antonio Filosa as the new CEO, effective June 23, 2024, following his extensive experience within the company [15] - Douyin e-commerce plans to reduce freight insurance costs for merchants by 5% to 15% starting June 6, 2024, potentially saving over 1 billion yuan in operating costs for merchants in the coming year [17]

Group 1 - Jia Ying Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [2] - ST United plans to acquire 100% of Run Tian Industrial through a combination of share issuance and cash payment, aiming to enhance its positioning as a comprehensive service provider in cultural tourism consumption [3] - Long Gao Co., Ltd. announced the restructuring of its controlling shareholder, Longyan Investment Development Group, which has established a new investment development group with a registered capital of 3 billion yuan [4] Group 2 - Sanyou Chemical's controlling shareholder intends to inject 100 million yuan into its subsidiary, Tangshan Sanyou Silicon Industry Co., Ltd., through a private agreement, without affecting the consolidation scope of the company [5] - ST Ji Pharmaceutical's stock will be delisted on May 29, 2025, due to a continuous closing price below 1 yuan for twenty trading days, triggering termination of listing rules [6] - Taiji Industrial plans to repurchase shares worth 100 million to 120 million yuan, with a maximum repurchase price of 10.38 yuan per share [7] Group 3 - China Energy Construction's subsidiary has won a bid for a coal power project worth approximately 14.586 billion yuan, marking a significant contract win [8][9]

关于收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日收到中 国证券监督管理委员会（以下简称"中国证监会"）的《立案告知书》（证监立案 字 0062025010 号），因公司涉嫌信息披露违法违规，根据《中华人民共和国证券 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 证券代码：002198 证券简称：嘉应制药 公告编号：2025-033 广东嘉应制药股份有限公司 公司将积极配合中国证监会的相关工作，并严格按照规定及监管要求履行信 息披露义务。公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》 和巨潮资讯网（http://www.cninfo.com.cn），公司相关信息均以在上述指定信息披 露媒体登载的公告为准。敬请广大投资者关注公司相关公告，理性投资，注意投 资风险。 特此公告。 广东嘉应制药股份有限公司董事会 2025 年 5 月 29 日 ...